MONTE ROSA THERAPEUTICS, INC.
Last · NASDAQ$9.84-0.05 (-0.51%)close · yahoo · 16h ago
Market cap$839.48M85.3M sh
P/E · TTM-5.8fwd -5.1 · eps -1.71 · loss
Beta1.37vs S&P 500
Div yield0.00%annual · TTM
52w range
$8.943$25.77
Volume1.1Msession
| Revenue | $13.2M |
|---|---|
| Operating income | $-99.2M |
| Net income | $-87.9M |
| Free cash flow | $-88.1M |
| Operating margin | -752.5% |
| Net margin | -667.0% |
| Return on equity | -18.0% |
| Period | 2026 |
Loading chart…
Upcoming earnings
1:30 PM UTC+1
Period
Sep 2026
Est. EPS
−$0.20
Est. revenue
33.9M
Press & signals
- GlobeNewswire
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Monte Rosa Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- GlobeNewswire
Monte Rosa Therapeutics Announces Second Quarter 2026 Financial Results and Business Updates
The rest of this company's wire — with summaries and source links — is part of Pro.
See plansDocuments
FormReporting forFiledFlags